Top Page
Cochlear
(Sydney:COH)
Cochlear (COH) vs. iShares MSCI Australia ETF (EWA)
Cochlear Business Overview & Revenue Model
Cochlear Earnings Call Summary
Cochlear Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36B | 2.34B | 2.24B | 1.94B | 1.64B | 1.49B |
| Gross Profit | 1.74B | 1.73B | 1.67B | 1.47B | 1.23B | 1.08B |
| EBITDA | 610.20M | 619.90M | 579.50M | 487.10M | 475.40M | 451.90M |
| Net Income | 388.90M | 388.90M | 356.80M | 300.60M | 289.10M | 326.50M |
Balance Sheet | ||||||
| Total Assets | 2.83B | 2.83B | 2.75B | 2.57B | 2.47B | 2.43B |
| Cash, Cash Equivalents and Short-Term Investments | 275.70M | 275.70M | 513.60M | 555.50M | 629.30M | 609.60M |
| Total Debt | 235.70M | 235.70M | 243.70M | 201.80M | 253.90M | 264.30M |
| Total Liabilities | 874.70M | 874.70M | 904.60M | 819.90M | 779.40M | 736.50M |
| Stockholders Equity | 1.95B | 1.95B | 1.84B | 1.75B | 1.69B | 1.69B |
Cash Flow | ||||||
| Free Cash Flow | 175.20M | 135.00M | 299.00M | 266.50M | 299.30M | 198.70M |
| Operating Cash Flow | 237.60M | 237.60M | 388.80M | 362.40M | 376.50M | 265.40M |
| Investing Cash Flow | -115.20M | -115.20M | -105.70M | -125.70M | -138.90M | 279.90M |
| Financing Cash Flow | -366.90M | -366.90M | -323.80M | -310.40M | -220.70M | -495.10M |
Cochlear Technical Analysis
Cochlear Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $18.36B | 47.23 | 20.11% | 1.51% | 4.32% | 9.24% | |
61 Neutral | AU$274.30M | -78.71 | -4.06% | ― | 20.36% | 64.81% | |
58 Neutral | $891.19M | 66.49 | 16.49% | ― | 23.31% | 151.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$176.12M | -16.52 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
41 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% |
Cochlear Corporate Events
Cochlear Limited has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). The announcement involves the issuance of 77 ordinary fully paid securities under an employee incentive scheme, which are set to be quoted on October 29, 2025. This move is part of Cochlear’s ongoing efforts to incentivize its workforce and align employee interests with company performance, potentially strengthening its market position and stakeholder relations.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$320.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited announced the results of its 2025 Annual General Meeting, where all resolutions were carried, indicating strong shareholder support. The meeting results reflect Cochlear’s stable governance and strategic direction, potentially reinforcing its position in the medical device industry and assuring stakeholders of its continued commitment to innovation and growth.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$280.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited’s 2025 Annual General Meeting highlighted its continued leadership in the implantable hearing solutions industry, emphasizing its commitment to innovation and long-term growth. The company reported significant achievements, including helping over 53,000 individuals with cochlear or acoustic implants, which have been estimated to provide a net societal benefit of over $9 billion. Additionally, a recent study from South Korea underscored the cognitive benefits of cochlear implants over hearing aids, showing a reduced risk of dementia for users with severe to profound hearing loss.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$280.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited announced the cessation of certain securities due to the lapse of conditional rights, which were not met or became incapable of being satisfied by the end of September 2025. This cessation involves options, performance rights, and service rights, impacting the company’s issued capital and potentially influencing investor perceptions and market dynamics.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced the issuance of 42,880 unquoted equity securities, which were converted from options or other convertible securities. This move could potentially impact the company’s financial structure and market positioning by increasing the number of shares in circulation, which may influence shareholder value and investment appeal.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited announced the cessation of 500 ordinary fully paid securities as part of an on-market buy-back, effective September 30, 2025. This move is part of the company’s capital management strategy, which may impact its financial structure and shareholder value, reflecting its commitment to optimizing capital allocation.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$280.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced a daily update on its ongoing on-market buy-back program, with a total of 98,800 securities bought back before the previous day and an additional 500 securities acquired on the previous day. This buy-back initiative is part of Cochlear’s strategy to optimize its capital structure and potentially enhance shareholder value by reducing the number of outstanding shares.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$320.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has updated its previous announcement regarding the dividend distribution for its ordinary fully paid securities. The update pertains to currency information related to the dividend for the period ending June 30, 2025. This adjustment may affect stakeholders’ financial planning and reflects the company’s commitment to transparent communication with its investors.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$320.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced the details for its 2025 Annual General Meeting (AGM), scheduled for October 23, 2025. The meeting will be conducted in a hybrid format, allowing shareholders to participate either in person at the company’s global headquarters or online. This approach aims to accommodate diverse shareholder preferences and ensure broader participation. The AGM will cover formal business matters, and shareholders are encouraged to submit questions in advance and vote either directly or through a proxy. The hybrid meeting format reflects Cochlear’s commitment to accessibility and engagement with its stakeholders.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$320.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced the issuance of 791 ordinary fully paid securities, effective September 5, 2025. This move reflects the company’s ongoing efforts to manage its equity structure and potentially enhance its financial flexibility, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$328.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced a change in the interests of its director, Diggory William Howitt, involving the acquisition and disposal of shares and options. The changes reflect a strategic adjustment in the director’s holdings, with implications for the company’s governance and potential market perception.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$327.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited’s recent earnings call presented a balanced narrative of achievements and challenges. The company celebrated the successful launch of the Nexa system and growth in specific product segments, yet faced hurdles such as declining services revenue, slower overall sales growth, and margin pressures. The outlook was cautiously optimistic, with expectations of growth driven by new product launches, but also acknowledged ongoing uncertainties in key markets.
Cochlear Limited has announced a change in the shareholding of its director, Michael del Prado, who has acquired 75 additional fully paid ordinary shares in the company. This purchase was made on the United States over-the-counter market, increasing his total holdings to 1,016 shares. This transaction reflects the director’s growing interest in the company and may signal confidence in its future performance.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$327.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited announced a change in the director’s interest notice, where Christine Frances McLoughlin transferred 1,900 shares from C F McLoughlin Super Investments Pty Ltd to Dundas Street Investments Pty Ltd. This off-market transfer reflects an internal reallocation of shares, with no net change in the total number of shares held by the director, potentially indicating strategic financial management within the company.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$327.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced a change in the interests of its director, Caroline Louise Clarke, involving the acquisition of 418 fully paid ordinary shares through on-market trades. This change reflects a strategic adjustment in the director’s investment in the company, potentially signaling confidence in Cochlear’s market performance and future prospects.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$329.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited is a global leader in implantable hearing solutions, specializing in cochlear implants and sound processor upgrades, with a strong focus on innovation and research in the healthcare equipment sector.
Cochlear Limited has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). This move involves the issuance of fully paid ordinary securities under an employee incentive scheme, reflecting the company’s ongoing efforts to align employee interests with corporate growth. The announcement indicates Cochlear’s strategic focus on enhancing its market presence and operational capabilities, potentially impacting its stakeholders positively by fostering a more engaged workforce.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced the application for the quotation of 1,774 ordinary fully paid securities on the Australian Securities Exchange (ASX), with the issue date set for August 18, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced an extension of its existing on-market buy-back program for its fully paid ordinary shares. This move indicates the company’s commitment to optimizing its capital structure and potentially enhancing shareholder value, reflecting a strategic approach to managing its financial resources.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has released its Tax Contribution Report for 2025, detailing its tax strategy, governance, and international tax dealings. The report highlights the company’s approach to risk management in taxation and its engagement with global revenue authorities, emphasizing transparency and compliance. This announcement underscores Cochlear’s commitment to responsible tax practices, which could enhance its reputation and trust among stakeholders.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited reported a 4% increase in sales revenue for FY25, reaching $2,356 million, driven by strong growth in cochlear and acoustic implant sales, although services revenue declined. A significant highlight was the launch of the Cochlear Nucleus Nexa System, the first smart cochlear implant with upgradeable firmware, which is expected to drive revenue growth in developed markets. Despite a modest loss in market share due to regulatory delays, the company maintained a global market share above 60%. The adults and seniors segment saw strong growth, while the children’s segment experienced a slight decline. Emerging markets showed over 20% unit growth, with a surge in the second half of the year. Services revenue faced challenges due to high satisfaction with existing products and cost-of-living pressures in the US. Acoustics revenue grew by 8%, supported by the Cochlear Osia Implant’s success and expansion into new markets.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced a new dividend distribution for its ordinary fully paid shares, with a distribution amount of AUD 2.15. The dividend relates to a six-month period ending on June 30, 2025, with key dates including an ex-date of September 18, 2025, and a payment date of October 13, 2025. This announcement reflects the company’s ongoing financial performance and commitment to delivering value to its shareholders.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced the Nucleus Nexa System, a groundbreaking cochlear implant system featuring upgradeable firmware, which allows users to access future innovations seamlessly. The Nucleus 8 Nexa Sound Processor, noted for being the smallest and lightest with an all-day battery life, enhances patient convenience by securely storing hearing settings on the implant, reducing the need for clinic visits.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited announced its preliminary final report for the fiscal year ending June 30, 2025, showing a 4% increase in sales revenue to A$2,355.8 million and a 9% rise in net profit attributable to shareholders to A$388.9 million. The company’s earnings before interest and taxes (EBIT) also grew by 9%, reflecting strong operational performance. The dividend per share increased by 5% to A$4.30, indicating a positive outlook for shareholders. These results underscore Cochlear’s robust financial health and its solid positioning in the medical device industry, with implications for continued growth and shareholder value.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced that its 2025 annual general meeting will be held as a hybrid event on October 23, 2025. The deadline for director nominations, excluding those recommended by the Board, is set for August 21, 2025. This announcement is significant for stakeholders as it outlines the timeline for governance activities and provides a framework for shareholder engagement.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.